"The discussion highlights a potential investment opportunity in $SG, drawing comparisons to Biovica, which offers similar tests at a lower cost, suggesting that $SG may be undervalued. Concerns about the lack of attention and discussion surrounding the stock were also noted, indicating a possible disconnect between its perceived value and market awareness."